This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Sage Therapeutics said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer’s disease after it failed to meet the main goal of a late-stage…
Reuters Health Information